| Attributes | Values |
|---|
| rdf:type
| |
| Description
| - Byla provedena preventivní vakcinace experimentálních BALB/c myší DNA vakcínou exprimující hsp90 protein z Candida albicans a vakcinace tímto proteinem připraveným rekombinantní technologií. Efektivita byla testována na modelu systémové kandidózy. Z mikrobiologicky ověřeného kmene C. albicans byla izolována mRNA hsp90, přepsána do cDNA a klonována do vakcinačního plasmidu pVAX1. Byly použity dvě metody aplikace DNA: intramuskulární (i.m.) nebo intradermální (i.d.) injekce. Rekombinantní protein byl injikován ve Freundově adjuvans i.d.; kontrolní skupině byl aplikován PBS nebo Freundovo adjuvans. Myši byly dvakrát vakcinovány s odstupem 19 dní. Tři týdny po druhé dávce byly myši i.v. infikovány 5x10exp6 CFU živých C. albicans. I.d. DNA vakcinace prodloužila přežívání myší vůči kontrolní skupině s Freundovým adjuvans o 39% a vůči skupině s PBS o 64%. I.m. DNA vakcinace nebyla spojena s průkazem protektivity. Sérové hladiny IgG imunoglobulinů specificky reagujících s hsp90 C. albicans korelovaly s přežív (cs)
- ABSTRACT. Preventive vaccination by a hsp90-expressing DNA vaccine and recombinant hsp90 proteinvaccine, both derived from the Candida albicans hsp90 using BALB-c mouse model of systemic candidiasis,was performed. Hsp90 mRNA was cloned from a clinical isolate of C. albicans, converted to cDNA andcloned into vaccination plasmid pVAX1. Two methods of DNA application were tested: intramuscular (i.m.)and intradermal (i.d.) injection. Recombinant protein was applied by i.d. injection with Freund's adjuvant;the control groups received PBS or Freund's adjuvant only. Mice were vaccinated and after 19 d re-vaccinated.After 3 weeks, the mice were challenged with the live C. albicans in a dose of 5 x 106 CFU per mouse.After the challenge, the mice vaccinated i.d. with DNA vaccine survived for 39 and 64 % longer comparedto those receiving Freund's adjuvant and/or PBS, respectively. The i.m. application of the DNA vaccine didnot provide any significant protectivity. The serum level of anti-candida-h
- ABSTRACT. Preventive vaccination by a hsp90-expressing DNA vaccine and recombinant hsp90 proteinvaccine, both derived from the Candida albicans hsp90 using BALB-c mouse model of systemic candidiasis,was performed. Hsp90 mRNA was cloned from a clinical isolate of C. albicans, converted to cDNA andcloned into vaccination plasmid pVAX1. Two methods of DNA application were tested: intramuscular (i.m.)and intradermal (i.d.) injection. Recombinant protein was applied by i.d. injection with Freund's adjuvant;the control groups received PBS or Freund's adjuvant only. Mice were vaccinated and after 19 d re-vaccinated.After 3 weeks, the mice were challenged with the live C. albicans in a dose of 5 x 106 CFU per mouse.After the challenge, the mice vaccinated i.d. with DNA vaccine survived for 39 and 64 % longer comparedto those receiving Freund's adjuvant and/or PBS, respectively. The i.m. application of the DNA vaccine didnot provide any significant protectivity. The serum level of anti-candida-h (en)
|
| Title
| - Comparison of Protective Effect of Protein and DNA Vaccines hsp90 in Murine Model of Systemic Candidiasis
- Comparison of Protective Effect of Protein and DNA Vaccines hsp90 in Murine Model of Systemic Candidiasis (en)
- Srovnání protektivního efektu proteinové a DNA vakcín hsp90 na modelu systémové kandidózy experimentálních myší. (cs)
|
| skos:prefLabel
| - Comparison of Protective Effect of Protein and DNA Vaccines hsp90 in Murine Model of Systemic Candidiasis
- Comparison of Protective Effect of Protein and DNA Vaccines hsp90 in Murine Model of Systemic Candidiasis (en)
- Srovnání protektivního efektu proteinové a DNA vakcín hsp90 na modelu systémové kandidózy experimentálních myší. (cs)
|
| skos:notation
| - RIV/61989592:15110/05:00001983!RIV06-MSM-15110___
|
| http://linked.open.../vavai/riv/strany
| |
| http://linked.open...avai/riv/aktivita
| |
| http://linked.open...avai/riv/aktivity
| |
| http://linked.open...iv/cisloPeriodika
| |
| http://linked.open...vai/riv/dodaniDat
| |
| http://linked.open...aciTvurceVysledku
| |
| http://linked.open.../riv/druhVysledku
| |
| http://linked.open...iv/duvernostUdaju
| |
| http://linked.open...titaPredkladatele
| |
| http://linked.open...dnocenehoVysledku
| |
| http://linked.open...ai/riv/idVysledku
| - RIV/61989592:15110/05:00001983
|
| http://linked.open...riv/jazykVysledku
| |
| http://linked.open.../riv/klicovaSlova
| - DNA; vaccine; hsp90; candida (en)
|
| http://linked.open.../riv/klicoveSlovo
| |
| http://linked.open...odStatuVydavatele
| |
| http://linked.open...ontrolniKodProRIV
| |
| http://linked.open...i/riv/nazevZdroje
| |
| http://linked.open...in/vavai/riv/obor
| |
| http://linked.open...ichTvurcuVysledku
| |
| http://linked.open...cetTvurcuVysledku
| |
| http://linked.open...UplatneniVysledku
| |
| http://linked.open...v/svazekPeriodika
| |
| http://linked.open...iv/tvurceVysledku
| - Kolář, Zdeněk
- Raška, Milan
- Weigl, Evžen
- Běláková, Jana
- Kafková, Leona
- Růžičková, Katharine
- Wudattu, Nalini K.
- Šebestová, Martina
|
| http://linked.open...n/vavai/riv/zamer
| |
| issn
| |
| number of pages
| |
| http://localhost/t...ganizacniJednotka
| |
![[RDF Data]](/fct/images/sw-rdf-blue.png)
![[cxml]](/fct/images/cxml_doc.png)
![[csv]](/fct/images/csv_doc.png)
![[text]](/fct/images/ntriples_doc.png)
![[turtle]](/fct/images/n3turtle_doc.png)
![[ld+json]](/fct/images/jsonld_doc.png)
![[rdf+json]](/fct/images/json_doc.png)
![[rdf+xml]](/fct/images/xml_doc.png)
![[atom+xml]](/fct/images/atom_doc.png)
![[html]](/fct/images/html_doc.png)